Roche said the phase 3 trials of Ronapreve had shown that high-risk non-hospitalised patients treated with the drug had a 70 percent reduction in subsequent hospitalisation and death.It also shorted the period of symptomatic illness by four days, Roche said, adding that the phase 1 trials had showed the safety and tolerability of the drug among the Japanese population. 不是神药, 还好吧。
世界第一怎么算出来的?
没听说过,那是有多厉害啊?
Source?
不是神药, 还好吧。
这个就是罗氏生产的Regeneron
70%很好啦。但是不知道这种受不受变种影响啊
既然这些不是神药,那么疫苗产生的抗体呢?